Compare GCT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCT | PCRX |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 999.0M |
| IPO Year | 2021 | 2010 |
| Metric | GCT | PCRX |
|---|---|---|
| Price | $38.01 | $25.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $33.00 | $30.25 |
| AVG Volume (30 Days) | ★ 615.7K | 448.9K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.70 | ★ 107.44 |
| EPS | ★ 1.04 | 0.07 |
| Revenue | ★ $1,161,042,000.00 | $541,533,000.00 |
| Revenue This Year | $14.43 | $6.78 |
| Revenue Next Year | $6.78 | $8.54 |
| P/E Ratio | ★ $36.50 | $363.86 |
| Revenue Growth | ★ 64.96 | 26.04 |
| 52 Week Low | $20.71 | $18.80 |
| 52 Week High | $51.82 | $27.64 |
| Indicator | GCT | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.52 | 60.55 |
| Support Level | $37.46 | $22.03 |
| Resistance Level | $43.64 | $26.94 |
| Average True Range (ATR) | 1.49 | 0.94 |
| MACD | 0.72 | -0.03 |
| Stochastic Oscillator | 84.18 | 47.53 |
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia with resellers in the U.S., Asia, and Europe to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price. It earns the majority of its revenue from the United States.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.